RxDoctor Payments Data

Scott Dorfner, DO

Internal Medicine · Burlington, NJNPI 1699783985

Payments from drug & device makers

$6,302in general payments, 2019–2025

Across 382 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$473
  • Boehringer Ingelheim$422
  • Lilly USA, LLC$414
  • Abbott$369
  • Amgen$339
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,281100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,302 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$188,824
Medicare patients
445
Services billed
2,682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$150,889
JardianceEmpagliflozin99$136,845
OzempicSemaglutide93$115,660
TrulicityDulaglutide60$81,919
FarxigaDapagliflozin Propanediol62$67,230
JanuviaSitagliptin Phosphate50$62,069
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$56,458
MounjaroTirzepatide26$52,191
Budesonide ErBudesonide20$44,500
XareltoRivaroxaban30$23,293
Repatha SureclickEvolocumab19$20,913
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$16,497
LinzessLinaclotide18$15,837
Breo ElliptaFluticasone/Vilanterol32$14,415
Tresiba Flextouch U-100Insulin Degludec18$13,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$294$150,889125 claims
Boehringer IngelheimJardiance, Spiriva Respimat$422$143,629110 claims
Lilly USA, LLCTrulicity, Mounjaro$414$134,10986 claims
Novo NordiskOzempic$1,216$115,66093 claims
AstraZenecaFarxiga, Symbicort$319$71,23377 claims
GSKTrelegy Ellipta, Breo Ellipta$280$70,872107 claims
MerckJanuvia, Belsomra$99$67,26362 claims
Johnson & JohnsonXarelto$104$23,29330 claims
AbbVieLinzess, Synthroid$473$19,79778 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Burlington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →